Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)

Completed

• Conditions: Choroidal Neovascular Age-related Macular Degeneration; Age-related Macular Degeneration

• Registration Number: NCT01682382
• Lead Sponsor: Sequenom, Inc.

Brief Summary

Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there is an association between genetics, MPOD and the risk of progression to wet AMD.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-08
• Study First Submitted: 2012-09-06
• Study First Submitted QC: 2012-09-06
• Study First Posted: 2012-09-10
• Primary Completion: 2013-08
• Study Completion: 2013-10
• Status Verified: 2014-01
• Last Update Submitted: 2014-01-16
• Last Update Posted: 2014-01-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• subject is diagnosed with either CNV, dry AMD or is an age-matched control
• self reported as non-Hispanic Caucasian
• 60 years of age or older
• provides signed and dated informed consent
• agrees to provide 10 mL of whole blood and two buccal swabs

Exclusion Criteria

• previous donation under this protocol

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Association between a genetic variant in the CFH gene and risk of progression to CNV	Baseline	DNA extracted from blood and buccal cells collected from subjects with either CNV, dry AMD, and age-matched controls will be analyzed to investigate a genetic variant in the CFH gene and its association with risk of progression to CNV

Secondary Outcome Measures

Name	Time	Method
Genetic correlation between MPOD and risk of progression to CNV	baseline	DNA extracted from blood and buccal cells collected from subjects with either CNV, dry AMD, and age-matched controls will be analyzed to investigate the correlation between genetics, MPOD, and risk of progression to CNV

Trial Locations

Locations (1)

Morris Eye Group; 🇺🇸 Encinitas, California, United States